更新于：2024-11-04
Blonanserin
布南色林
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 Blonanserin (JAN/INN)、LONASEN Tape、AD 5423 + [6] |
作用机制 5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 日本 (2008-01-25), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C23H30FN3 |
InChIKeyXVGOZDAJGBALKS-UHFFFAOYSA-N |
CAS号132810-10-7 |
关联
56
项与 布南色林 相关的临床试验浙江金华康恩贝生物制药有限公司生产的布南色林片与持证商为Sumitomo Dainippon Pharma Co.，Ltd的布南色林片（规格：4 mg，商品名：洛珊®）在中国健康受试者中进行的单中心、随机、开放、两制剂、单次给药、两序列、四周期、完全重复交叉设计空腹/餐后状态下的生物等效性研究。
Comparative effectiveness and tolerability of Amisulpride versus Blonanserin augmentation to Clozapine in Treatment Resistant Schizophrenia - nil
布南色林片（规格：4mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、交叉生物等效性试验
100 项与 布南色林 相关的临床结果
登录后查看更多信息
100 项与 布南色林 相关的转化医学
登录后查看更多信息
100 项与 布南色林 相关的专利（医药）
登录后查看更多信息
186
项与 布南色林 相关的文献（医药）2024-12-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Preparation and release pattern study of long-term controlled release Blonanserin microspheres
Article
作者: Lin, Guimei ; Zhou, Jiamin ; Li, Lian ; Qiu, Shengnan ; Wan, Xiaoyu ; Liu, Yingying ; Li, Yaqi ; Zhang, Yankun ; Zang, Hengchang ; Li, Zengmei ; Shi, Yanbin ; Fu, Xianglei ; Chen, Xiangqin
To prepare a PLGA microsphere loaded with the antipsychotic Blonanserin without release leg period and released in a near-zero model for long time, in this study, 15 kDa and 75 kDa PLGA were chosen to be mixed with different ratios, and Blonanserin microspheres (Bn-MS) without significant differences in the particle size, drug loading capacity, and encapsulation rate were prepared by microfluidics. The release kinetic model was fitted to the release behavior by monitoring the changes in particle size and morphology during the Bn-MS release to investigate microspheres' in vitro release pattern. The results showed that the addition of appropriate ratios of mixed molecular weights to Bn-MS could eliminate the release hysteresis period. When the ratio of 15 kDa and 75 kDa was 1:9 (F3), the Bn-MS had a low burst release rate, moderate release rate, no release hysteresis period, a long release period of up to 35 days, and a stable release pattern close to the zero level. The results of the release mechanism study indicated that the hybrid PLGA improved the release behavior of the microspheres by adjusting the dissolution degradation rate of Bn-MS, which in turn affected the release mechanism of the microspheres.
2024-10-18BMC Psychiatry
A case report of adolescent lactation due to the drug blonanserin.
Article
作者: Wang, Chongze ; Yi, Zhenghui ; Lv, Qinyu ; Tang, Peiyuan ; Hong, Wu
BACKGROUND:
Second-generation antipsychotic drugs are increasingly used to treat depressive disorders with psychotic symptoms. In addition to effectively managing psychotic symptoms, second-generation antipsychotics can also result in adverse drug reactions in patients, which should not be underestimated.
CASE PRESENTATION:
We report the case of 14 years old unmarried female patient with depression. At first, she started with moping and gradually developed into self-injury and whispering. After antidepressant treatment combined with the second-generation antipsychotic drug blonanserin, the patient's psychotic and depressive symptoms improved significantly, while the patient developed lactation, which stopped after the medication was changed.
CONCLUSIONS:
Although Blonanserin's clinical trials have reported rare adverse reactions like elevated prolactin levels and even lactation, caution is still needed in clinical application of the drug. This case is expected to improve psychiatrists' choice of antidepressant therapy in combination with antipsychotic drugs.
2024-08-01Journal of palliative medicine
Successful Management of Terminal Delirium With Transdermal Blonanserin Patch in a Terminally Ill Cancer Patient
Article
作者: Nishiofuku, Hideyuki ; Mori, Masanori ; Miyagi, Akemi ; Yokomichi, Naosuke ; Ishizuka, Masato ; Sugiyama, Koichi ; Morita, Tatsuya ; Imai, Kengo ; Takashina, Yoshiaki ; Sakuma, Yumi
Delirium is a distressing condition in terminally ill cancer patients, often treated with antipsychotics. Administering them orally, subcutaneously, or intravenously can be challenging in severely agitated patients. Transdermal antipsychotic patches offer an alternative, but their use for terminal delirium remains underexplored. We present the case of a 73-year-old man with advanced diffuse large B cell lymphoma who developed severe mixed delirium during third-line chemotherapy. Nonpharmacological interventions and oral risperidone plus intravenous haloperidol failed to improve his condition. Subsequently, a transdermal blonanserin patch was applied, resulting in the resolution of hallucinations on day 1 and agitation on day 3, allowing improved communication. The patch was easily applied daily without notable adverse events. However, he deteriorated a week later with an estimated survival of days, ultimately requiring continuous midazolam for refractory agitation. This case underscores the potential of transdermal blonanserin patches for delirium in terminally ill cancer patients, emphasizing the need for future prospective studies.
100 项与 布南色林 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 精神分裂症 | 日本 | 2008-01-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 580 | DSP-5423P Placebo (DSP-5423P Placebo) | 夢蓋選鏇襯齋網襯範選(積壓醖窪願衊鏇鑰遞憲) = 網鬱積壓鑰網壓積積選 鹽壓襯顧蓋顧鏇廠夢淵 (構觸鹽繭築繭鏇選觸淵, 製衊範簾鑰壓網襯廠廠 ~ 艱鑰鏇簾艱繭艱醖襯觸) 更多 | - | 2020-12-23 | ||
(DSP-5423P 40mg) | 夢蓋選鏇襯齋網襯範選(積壓醖窪願衊鏇鑰遞憲) = 觸獵網窪簾獵淵壓蓋廠 鹽壓襯顧蓋顧鏇廠夢淵 (構觸鹽繭築繭鏇選觸淵, 憲夢製鏇夢壓獵鑰網糧 ~ 積糧鹽鬱蓋壓壓遞願範) 更多 | ||||||
临床3期 | 200 | (DSP-5423P (Cohort 1)) | 艱艱顧選鑰餘憲選淵窪(衊範蓋願積鏇顧膚膚範) = 膚醖積簾鑰餘獵醖獵築 觸願遞獵蓋鹹艱鑰鹽觸 (夢築鬱鹹願鏇醖蓋繭餘, 繭糧範築構艱網夢艱膚 ~ 鏇淵壓範壓餘網衊製觸) 更多 | - | 2020-11-19 | ||
(DSP-5423P (Cohort 2)) | 艱艱顧選鑰餘憲選淵窪(衊範蓋願積鏇顧膚膚範) = 繭餘簾觸夢簾餘壓範膚 觸願遞獵蓋鹹艱鑰鹽觸 (夢築鬱鹹願鏇醖蓋繭餘, 夢衊鹹顧衊餘遞顧願夢 ~ 齋淵窪鹹顧製餘醖糧憲) 更多 | ||||||
临床3期 | 267 | (Blonanserin) | 選範衊顧膚夢餘鹽範餘(糧範糧願餘壓願鑰襯鑰) = 襯憲膚鏇壓壓顧餘製鏇 夢鹹醖廠築蓋鏇鑰糧簾 (醖蓋艱鏇鹹製簾齋餘鹹, 築觸艱廠顧餘壓窪壓簾 ~ 蓋積繭艱鹽製築膚獵襯) 更多 | - | 2018-11-26 | ||
(Risperidone) | 選範衊顧膚夢餘鹽範餘(糧範糧願餘壓願鑰襯鑰) = 構淵顧艱構構餘願繭選 夢鹹醖廠築蓋鏇鑰糧簾 (醖蓋艱鏇鹹製簾齋餘鹹, 遞範構淵餘繭衊觸蓋鏇 ~ 鬱鹽鹹壓繭獵製糧鹽遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用